Zura Bio (ZURA) Competitors

$5.06 -0.26 (-4.89%)

As of 02:27 PM Eastern

ZURA vs. MESO, CAPR, INBX, ANAB, and GLPG

Should you be buying Zura Bio stock or one of its competitors? The main competitors of Zura Bio include Mesoblast (MESO), Capricor Therapeutics (CAPR), Inhibrx Biosciences (INBX), AnaptysBio (ANAB), and Galapagos (GLPG). These companies are all part of the "pharmaceutical products" industry.

How does Zura Bio compare to Mesoblast?

Zura Bio (NASDAQ:ZURA) and Mesoblast (NASDAQ:MESO) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, earnings, risk, analyst recommendations, valuation and dividends.

: Zura Bio currently has a consensus target price of $10.75, indicating a potential upside of 112.45%. Given Zura Bio's stronger consensus rating and higher probable upside, equities research analysts clearly believe Zura Bio is more favorable than Mesoblast.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zura Bio
1 Sell rating(s)
1 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.67
Mesoblast
1 Sell rating(s)

1 Hold rating(s)

0 Buy rating(s)

1 Strong Buy rating(s)
2.33
: Zura Bio has higher earnings, but lower revenue than Mesoblast. Mesoblast is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zura Bio N/A N/A -$99.35M -$1.06 N/A
Mesoblast $65.38M 31.13 -$102.14M -$0.54 N/A
: Mesoblast's return on equity of 0.00% beat Zura Bio's return on equity.
Company Net Margins Return on Equity Return on Assets
Zura Bio N/A -59.06% -48.04%
Mesoblast N/A N/A N/A
: Zura Bio has a beta of 0.09, meaning that its share price is 91% less volatile than the S&P 500. Comparatively, Mesoblast has a beta of 2.1, meaning that its share price is 110% more volatile than the S&P 500.
: 61.1% of Zura Bio shares are held by institutional investors. Comparatively, 1.4% of Mesoblast shares are held by institutional investors. 14.2% of Zura Bio shares are held by insiders. Comparatively, 18.8% of Mesoblast shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
: In the previous week, Mesoblast had 8 more articles in the media than Zura Bio. MarketBeat recorded 10 mentions for Mesoblast and 2 mentions for Zura Bio. Zura Bio's average media sentiment score of 0.00 beat Mesoblast's score of -0.20 indicating that Zura Bio is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zura Bio
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Mesoblast
1 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
2 Negative mention(s)
2 Very Negative mention(s)
Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Mesoblast	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.06	N/A
Mesoblast	$65.38M	31.13	-$102.14M	-$0.54	N/A

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-59.06%	-48.04%
Mesoblast	N/A	N/A	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zura Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Mesoblast	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	2 Negative mention(s)	2 Very Negative mention(s)	Neutral

Summary

Zura Bio and Mesoblast tied by winning 7 of the 14 factors compared between the two stocks.

How does Zura Bio compare to Capricor Therapeutics?

Capricor Therapeutics (NASDAQ:CAPR) and Zura Bio (NASDAQ:ZURA) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

: Capricor Therapeutics currently has a consensus target price of $46.09, indicating a potential upside of 40.89%. Zura Bio has a consensus target price of $10.75, indicating a potential upside of 112.45%. Given Zura Bio's higher possible upside, analysts plainly believe Zura Bio is more favorable than Capricor Therapeutics.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Capricor Therapeutics
1 Sell rating(s)
0 Hold rating(s)

9 Buy rating(s)

0 Strong Buy rating(s)
2.80
Zura Bio
1 Sell rating(s)

1 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.67
: Zura Bio's return on equity of -59.06% beat Capricor Therapeutics' return on equity.
Company Net Margins Return on Equity Return on Assets
Capricor Therapeutics N/A -67.52% -54.59%
Zura Bio N/A -59.06% -48.04%
: In the previous week, Capricor Therapeutics had 8 more articles in the media than Zura Bio. MarketBeat recorded 10 mentions for Capricor Therapeutics and 2 mentions for Zura Bio. Capricor Therapeutics' average media sentiment score of 0.27 beat Zura Bio's score of 0.00 indicating that Capricor Therapeutics is being referred to more favorably in the media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Capricor Therapeutics
4 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Zura Bio
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Capricor Therapeutics has a beta of 0.48, meaning that its stock price is 52% less volatile than the S&P 500. Comparatively, Zura Bio has a beta of 0.09, meaning that its stock price is 91% less volatile than the S&P 500.
: Capricor Therapeutics is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Capricor Therapeutics N/A N/A -$105.04M -$2.26 N/A
Zura Bio N/A N/A -$99.35M -$1.06 N/A
: 21.7% of Capricor Therapeutics shares are held by institutional investors. Comparatively, 61.1% of Zura Bio shares are held by institutional investors. 9.2% of Capricor Therapeutics shares are held by insiders. Comparatively, 14.2% of Zura Bio shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capricor Therapeutics	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67

Company	Net Margins	Return on Equity	Return on Assets
Capricor Therapeutics	N/A	-67.52%	-54.59%
Zura Bio	N/A	-59.06%	-48.04%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Capricor Therapeutics	4 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zura Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capricor Therapeutics	N/A	N/A	-$105.04M	-$2.26	N/A
Zura Bio	N/A	N/A	-$99.35M	-$1.06	N/A

Summary

Zura Bio beats Capricor Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Zura Bio compare to Inhibrx Biosciences?

Zura Bio (NASDAQ:ZURA) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, risk, media sentiment, profitability, dividends, analyst recommendations and valuation.

: Zura Bio presently has a consensus target price of $10.75, indicating a potential upside of 112.45%. Inhibrx Biosciences has a consensus target price of $150.00, indicating a potential upside of 16.39%. Given Zura Bio's stronger consensus rating and higher possible upside, equities research analysts plainly believe Zura Bio is more favorable than Inhibrx Biosciences.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zura Bio
1 Sell rating(s)
1 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.67
Inhibrx Biosciences
1 Sell rating(s)

3 Hold rating(s)

1 Buy rating(s)

1 Strong Buy rating(s)
2.33
: Zura Bio's return on equity of -59.06% beat Inhibrx Biosciences' return on equity.
Company Net Margins Return on Equity Return on Assets
Zura Bio N/A -59.06% -48.04%
Inhibrx Biosciences N/A -269.56% -71.94%
: In the previous week, Inhibrx Biosciences had 3 more articles in the media than Zura Bio. MarketBeat recorded 5 mentions for Inhibrx Biosciences and 2 mentions for Zura Bio. Inhibrx Biosciences' average media sentiment score of 0.28 beat Zura Bio's score of 0.00 indicating that Inhibrx Biosciences is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zura Bio
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Inhibrx Biosciences
1 Very Positive mention(s)
2 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
: Zura Bio has a beta of 0.09, meaning that its share price is 91% less volatile than the S&P 500. Comparatively, Inhibrx Biosciences has a beta of 3.88, meaning that its share price is 288% more volatile than the S&P 500.
: Zura Bio has higher earnings, but lower revenue than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zura Bio N/A N/A -$99.35M -$1.06 N/A
Inhibrx Biosciences $1.30M 1,448.06 -$140.05M -$9.04 N/A
: 61.1% of Zura Bio shares are owned by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are owned by institutional investors. 14.2% of Zura Bio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-59.06%	-48.04%
Inhibrx Biosciences	N/A	-269.56%	-71.94%

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zura Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inhibrx Biosciences	1 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.06	N/A
Inhibrx Biosciences	$1.30M	1,448.06	-$140.05M	-$9.04	N/A

Summary

Zura Bio beats Inhibrx Biosciences on 9 of the 14 factors compared between the two stocks.

How does Zura Bio compare to AnaptysBio?

Zura Bio (NASDAQ:ZURA) and AnaptysBio (NASDAQ:ANAB) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

: 61.1% of Zura Bio shares are owned by institutional investors. 14.2% of Zura Bio shares are owned by company insiders. Comparatively, 33.5% of AnaptysBio shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
: Zura Bio has a net margin of 0.00% compared to AnaptysBio's net margin of -5.64%. Zura Bio's return on equity of -59.06% beat AnaptysBio's return on equity.
Company Net Margins Return on Equity Return on Assets
Zura Bio N/A -59.06% -48.04%
AnaptysBio -5.64% -1,101.24% -3.59%
: Zura Bio presently has a consensus target price of $10.75, indicating a potential upside of 112.45%. AnaptysBio has a consensus target price of $76.18, indicating a potential upside of 9.50%. Given Zura Bio's higher probable upside, research analysts plainly believe Zura Bio is more favorable than AnaptysBio.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zura Bio
1 Sell rating(s)
1 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.67
AnaptysBio
1 Sell rating(s)

1 Hold rating(s)

10 Buy rating(s)

0 Strong Buy rating(s)
2.75
: Zura Bio has a beta of 0.09, meaning that its stock price is 91% less volatile than the S&P 500. Comparatively, AnaptysBio has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500.
: In the previous week, AnaptysBio had 4 more articles in the media than Zura Bio. MarketBeat recorded 6 mentions for AnaptysBio and 2 mentions for Zura Bio. AnaptysBio's average media sentiment score of 0.11 beat Zura Bio's score of 0.00 indicating that AnaptysBio is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zura Bio
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
AnaptysBio
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
: AnaptysBio has higher revenue and earnings than Zura Bio. AnaptysBio is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zura Bio N/A N/A -$99.35M -$1.06 N/A
AnaptysBio $234.60M 8.63 -$13.23M -$0.52 N/A

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-59.06%	-48.04%
AnaptysBio	-5.64%	-1,101.24%	-3.59%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
AnaptysBio	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zura Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
AnaptysBio	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.06	N/A
AnaptysBio	$234.60M	8.63	-$13.23M	-$0.52	N/A

Summary

AnaptysBio beats Zura Bio on 10 of the 16 factors compared between the two stocks.

How does Zura Bio compare to Galapagos?

Zura Bio (NASDAQ:ZURA) and Galapagos (NASDAQ:GLPG) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, risk, profitability, media sentiment, valuation, analyst recommendations, dividends and institutional ownership.

: Galapagos' return on equity of 0.00% beat Zura Bio's return on equity.
Company Net Margins Return on Equity Return on Assets
Zura Bio N/A -59.06% -48.04%
Galapagos N/A N/A N/A
: Zura Bio presently has a consensus target price of $10.75, indicating a potential upside of 112.45%. Galapagos has a consensus target price of $36.50, indicating a potential upside of 28.93%. Given Zura Bio's stronger consensus rating and higher probable upside, research analysts plainly believe Zura Bio is more favorable than Galapagos.
Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zura Bio
1 Sell rating(s)
1 Hold rating(s)

3 Buy rating(s)

1 Strong Buy rating(s)
2.67
Galapagos
1 Sell rating(s)

5 Hold rating(s)

0 Buy rating(s)

1 Strong Buy rating(s)
2.14
: Galapagos has higher revenue and earnings than Zura Bio. Galapagos is trading at a lower price-to-earnings ratio than Zura Bio, indicating that it is currently the more affordable of the two stocks.
Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Zura Bio N/A N/A -$99.35M -$1.06 N/A
Galapagos $1.11B 1.68 $363.05M -$1.57 N/A
: In the previous week, Galapagos had 5 more articles in the media than Zura Bio. MarketBeat recorded 7 mentions for Galapagos and 2 mentions for Zura Bio. Galapagos' average media sentiment score of 0.72 beat Zura Bio's score of 0.00 indicating that Galapagos is being referred to more favorably in the news media.
Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Zura Bio
0 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Galapagos
3 Very Positive mention(s)
1 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
: 61.1% of Zura Bio shares are owned by institutional investors. Comparatively, 32.5% of Galapagos shares are owned by institutional investors. 14.2% of Zura Bio shares are owned by company insiders. Comparatively, 2.9% of Galapagos shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
: Zura Bio has a beta of 0.09, meaning that its stock price is 91% less volatile than the S&P 500. Comparatively, Galapagos has a beta of 0.25, meaning that its stock price is 75% less volatile than the S&P 500.

Company	Net Margins	Return on Equity	Return on Assets
Zura Bio	N/A	-59.06%	-48.04%
Galapagos	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zura Bio	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.67
Galapagos	1 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.14

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Zura Bio	N/A	N/A	-$99.35M	-$1.06	N/A
Galapagos	$1.11B	1.68	$363.05M	-$1.57	N/A

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Zura Bio	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Galapagos	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Zura Bio and Galapagos tied by winning 7 of the 14 factors compared between the two stocks.

Get Zura Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ZURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ZURA vs. The Competition

Export

Metric	Zura Bio	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$479.62M	$3.38B	$6.24B	$11.87B
Dividend Yield	N/A	2.20%	2.73%	5.21%
P/E Ratio	-4.77	38.92	29.06	28.45
Price / Sales	N/A	158.54	475.43	61.47
Price / Cash	N/A	57.88	27.62	36.52
Price / Book	3.67	6.99	9.69	6.64
Net Income	-$99.35M	$23.62M	$3.55B	$332.53M
7 Day Performance	-4.53%	3.06%	1.46%	1.83%
1 Month Performance	-16.09%	6.56%	5.35%	8.98%
1 Year Performance	251.39%	65.81%	33.88%	39.30%

Zura Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ZURA Zura Bio	2.394 of 5 stars	$5.06 -4.9%	$10.75 +112.5%	N/A	$479.62M	N/A	N/A	3	Upcoming Earnings
MESO Mesoblast	1.2918 of 5 stars	$15.22 -0.7%	N/A	N/A	$1.97B	$17.20M	N/A	80
CAPR Capricor Therapeutics	2.1668 of 5 stars	$33.98 -3.2%	$46.09 +35.6%	N/A	$1.97B	$22.27M	N/A	101	News Coverage Upcoming Earnings Insider Trade
INBX Inhibrx Biosciences	1.7897 of 5 stars	$130.66 -0.6%	$150.00 +14.8%	N/A	$1.91B	$1.30M	N/A	166	Analyst Upgrade
ANAB AnaptysBio	2.1724 of 5 stars	$66.11 -0.7%	$76.36 +15.5%	N/A	$1.90B	$234.60M	N/A	100	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ZURA) was last updated on 5/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Zura Bio (ZURA) Competitors